C1酯酶抑制剂的抗组蛋白特性可防止肺损伤
研究探讨C1酯酶抑制剂(C1INH)能否在体内保护肺损伤并阐明机制。体外实验显示C1INH可结合所有类型组蛋白,该结合不依赖其蛋白酶抑制活性而依赖糖基化状态,其唾液酸化N-和O-聚糖对结合组蛋白及防止组蛋白诱导的细胞死亡至关重要。体内实验表明C1INH通过直接与细胞外组蛋白相互作用减轻博来霉素诱导的肺损伤,在急性呼吸窘迫综合征患者支气管肺泡灌洗液及多种肺损伤模型中检测到组蛋白-C1INH复合物。作者结论认为C1INH给药为组蛋白释放相关疾病提供了新的治疗选择。
要点
- C1INH通过直接结合细胞外组蛋白减轻博来霉素诱导的肺损伤。
- C1INH与组蛋白的结合不依赖其蛋白酶抑制活性,而依赖其糖基化状态。
- C1INH的唾液酸化N-和O-聚糖对结合组蛋白及防止组蛋白诱导的细胞死亡至关重要。
- 在ARDS患者支气管肺泡灌洗液及多种肺损伤模型中检测到组蛋白-C1INH复合物。
- 反应中心切割的C1INH可减轻静脉注射组蛋白引起的肺损伤。
研究设计与关键结果
- 研究为体外和体内实验,探讨C1INH对炎症过程的控制能力。
- 体外实验显示C1INH可结合所有类型组蛋白,该结合不依赖其蛋白酶抑制活性(使用反应中心切割的C1INH证实),而依赖其糖基化状态。
- C1INH的唾液酸化N-和O-聚糖不仅对其与组蛋白的相互作用必需,也对防止组蛋白诱导的细胞死亡必需。
- 体内实验显示C1INH通过直接与细胞外组蛋白相互作用减轻博来霉素诱导的肺损伤。
- 在ARDS患者支气管肺泡灌洗液及多种肺损伤模型中检测到组蛋白-C1INH复合物。
- 反应中心切割的C1INH可减轻静脉注射组蛋白引起的肺损伤。
证据类型、等级与局限
- 证据类型:体外实验与体内动物实验研究。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为C1INH给药为组蛋白释放相关疾病提供了新的治疗选择。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: Acute respiratory distress syndrome is characterized by alveolar epithelial cell injury, edema formation, and intraalveolar contact phase activation.
OBJECTIVES: To explore whether C1 esterase inhibitor (C1INH), an endogenous inhibitor of the contact phase, may protect from lung injury in vivo and to decipher the possible underlying mechanisms mediating protection.
METHODS: The ability of C1INH to control the inflammatory processes was studied in vitro and in vivo.
MEASUREMENTS AND MAIN RESULTS: Here, we demonstrate that application of C1INH alleviates bleomycin-induced lung injury via direct interaction with extracellular histones. In vitro, C1INH was found to bind all histone types. Interaction with histones was independent of its protease inhibitory activity, as demonstrated by the use of reactive-center-cleaved C1INH, but dependent on its glycosylation status. C1INH sialylated-N- and -O-glycans were not only essential for its interaction with histones but also to protect against histone-induced cell death. In vivo, histone-C1INH complexes were detected in bronchoalveolar lavage fluid from patients with acute respiratory distress syndrome and multiple models of lung injury. Furthermore, reactive-center-cleaved C1INH attenuated pulmonary damage evoked by intravenous histone instillation.
CONCLUSIONS: Collectively, C1INH administration provides a new therapeutic option for disorders associated with histone release.
参考来源
- Wygrecka M, Kosanovic D, Wujak L, et al. Antihistone Properties of C1 Esterase Inhibitor Protect against Lung Injury. Am J Respir Crit Care Med. 2017. PMID: 28005404. doi:10.1164/rccm.201604-0712OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。